Monitor for upcoming IND filings or clinical trial initiation announcements for IM1240, which would be the next major value inflection point. This data strengthens the platform's differentiation and could attract biotech partners or investors focused on next-gen immunotherapies, particularly in resistant solid tumors.
Price Chart
Executive Summary
Purple Biotech announced new preclinical data showing that its tri-specific antibody IM1240 demonstrated potent anti-tumor activity across all seven tested patient-derived tumor samples, including treatment-resistant cancers. The data highlight the critical role of the NKG2A arm in enhancing anti-tumor response and inducing tertiary lymphoid structures associated with improved clinical outcomes.
Key Facts
- New preclinical data show IM1240 induced anti-tumor responses in all 7 patient-derived tumor samples tested, including PD-1-resistant head and neck cancer and bladder cancer.
- The NKG2A arm of IM1240 was shown to significantly enhance anti-tumor activity and improve therapeutic index, with loss of efficacy observed when this arm was mutated.
- IM1240 induced mature tertiary lymphoid structures (TLS) in NSCLC biopsies—biomarkers linked to strong anti-tumor immunity and better prognosis.
- IM1240 is part of the CAPTN-3 platform, a conditionally activated, masked tri-specific antibody designed to target tumors while minimizing systemic toxicity.
- The company remains in clinical-stage development with no commercial products yet; these results support progression toward clinical trials.
Financial Impact
No immediate financial impact, but de-risked development pathway for IM1240 increases likelihood of partnerships or funding. Market cap remains small at $4M, suggesting high optionality value on clinical advancement.
Risk Factors
- Preclinical data may not translate to human clinical efficacy.
- Company has limited financial resources and no near-term revenue; dependent on financing or partnerships.
- Highly competitive immuno-oncology landscape with multiple T-cell engagers in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047709 |
| Document: ea028779601ex99-1.htm | 0001213900-26-047709 |
| Document: 0001213900-26-047709-index-headers.html | 0001213900-26-047709 |
| Document: 0001213900-26-047709-index.html | 0001213900-26-047709 |
| Document: 0001213900-26-047709.txt | 0001213900-26-047709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 6-K | $1.74 $1.55 | ▼ −11.21% | ▼ −10.71% | $1.44 (−17.24%) |
Sep 2, 2026 4w ago | 6-K | $1.98 $1.74 | ▼ −12.12% | ▼ −11.16% | $1.44 (−27.27%) |
Aug 10, 2026 7w ago | 6-K | $1.55 $1.56 | ▲ +0.65% | ▲ +1.05% | $1.44 (−7.10%) |
Aug 7, 2026 8w ago | 6-K | $1.43 $1.50 | ▲ +4.90% | ▲ +4.50% | $1.44 (+0.70%) |
May 15, 2026 20w ago | Press Release | $3.94 $2.88 | ▼ −26.90% | ▼ −27.87% | $1.44 (−63.45%) |
Apr 27, 2026 22w ago | 6-K | $4.59 $4.22 | ▼ −8.06% | ▼ −8.46% | $1.44 (−68.63%) |
Apr 23, 2026 23w ago | 6-K | $4.55 $4.23 | ▼ −7.03% | ▼ −8.51% | $1.44 (−68.35%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
Mar 13, 2026 29w ago | Press Release | $4.10 $3.98 | ▼ −2.93% | ▼ −0.81% | $1.44 (−64.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access